Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...